tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Matt O'brien, 647 are a BUY (86.27%), 97 are a HOLD (12.93%), 6 are a SELL (0.8%).
Analyst Matt O'brien, currently employed at PIPER SANDLER, carries an average stock price target met ratio of 63.27% that have a potential upside of 24.55% achieved within 165 days.
Matt O'brien’s has documented 1,663 price targets and ratings displayed on 58 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on TNDM, Tandem Diabetes Care at 07-Aug-2025.
Analyst best performing recommendations are on RMED (RA MEDICAL SYSTEMS).
The best stock recommendation documented was for RMED (RA MEDICAL SYSTEMS) at 8/13/2019. The price target of $1875 was fulfilled within 2 days with a profit of $362.5 (23.97%) receiving and performance score of 119.83.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold
$388
$6.98 (1.83%)
$355
2 years 11 months 7 days ago
(01-Nov-2022)
2/5 (40%)
$14.49 (3.88%)
88
Hold
$380
$-1.02 (-0.27%)
$235
2 years 11 months 7 days ago
(01-Nov-2022)
1/2 (50%)
$6.49 (1.74%)
36
Hold
$380
$-1.02 (-0.27%)
$350
2 years 11 months 8 days ago
(31-Oct-2022)
24/41 (58.54%)
$2.18 (0.58%)
138
Buy
$300
$-81.02 (-21.26%)
$425
2 years 11 months 26 days ago
(12-Oct-2022)
1/2 (50%)
$41.92 (16.24%)
19
Sell
$235
$-146.02 (-38.32%)
$275
3 years 2 months 24 days ago
(14-Jul-2022)
6/8 (75%)
$-33.23 (-12.39%)
143
Which stock is Matt O'brien is most bullish on?
Which stock is Matt O'brien is most reserved on?
What Year was the first public recommendation made by Matt O'brien?
